NEW YORK, June 9, 2026
Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human (FIH) clinical trial evaluating BLKR201, an investigational CNS-penetrant allosteric TYK2 inhibitor. The study, BLKR201-101-HV, is assessing the safety, tolerability, and pharmacokinetics of the therapy through single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in healthy volunteers. The milestone comes just five months after Formation Bio licensed the asset from Lynk Pharmaceuticals.
BLKR201 Advances into First-in-Human Clinical Testing
BLKR201 is a next-generation TYK2 inhibitor designed to regulate immune signaling within the central nervous system (CNS). The therapy combines CNS penetration with high target selectivity, potentially enabling treatment of autoimmune and inflammatory diseases where immune activity is concentrated within the brain and nervous system. The Phase 1 trial marks the first time BLKR201 has been evaluated in humans, with initial clinical data expected in early 2027.
AI-Driven Development Accelerated Clinical Progress
Formation Bio stated that its AI-native drug development platform enabled rapid evaluation of BLKR201’s biology, identification of potential therapeutic indications, and progression from licensing to clinical testing within five months. The company used AI-supported approaches across indication strategy, evidence generation, and clinical trial execution to accelerate development. BLKR201 is being advanced through Formation Bio’s subsidiary Bleecker Bio under the company’s hub-and-spoke development model.
Advertisement
Potential New Treatment Approach for CNS Immune Disorders
TYK2 is a clinically validated target involved in immune system regulation. Formation Bio believes BLKR201’s CNS-penetrant profile may create opportunities in diseases driven by central or compartmentalized immune pathways, including various autoimmune and inflammatory disorders. The company plans to use Phase 1 findings to guide future clinical development and evaluate the therapy’s potential across multiple neurological and immune-mediated conditions.
Source: Formation Bio press release
